You are here
FDA Pushes Perindopril Erbumine Review Up 90 Days
ACEON(R) is an angiotensin converting enzyme (ACE) inhibitor with enhanced tissue affinity approved in the United States for the treatment of patients with essential hypertension. The sNDA, which was granted a six month priority review by the FDA, seeks an expansion to the existing label based on the EUROPA (EUropean trial on Reduction Of cardiac events with Perindopril in patients with stable coronary Artery disease) study.
EUROPA, a multicenter, randomized, double-blind, placebo-controlled trial in 12,218 patients with stable coronary disease and without clinical heart failure, was designed to assess the ability of perindopril to reduce cardiovascular mortality, nonfatal myocardial infarction and cardiac arrest.
"We will be working closely with the FDA to complete the necessary activities to support the potential approval of the sNDA for this exciting potential new indication," said Harold H. Shlevin, Ph.D., president and chief executive officer of Solvay Pharmaceuticals, Inc. Solvay Pharmaceuticals holds the new drug application for ACEON(R).
"We continue to make progress in recruiting, hiring and training an outstanding cardiovascular sales team and we look forward to promoting ACEON(R) to cardiovascular specialists this summer, and then leveraging the commercial experience we gain with ACEON(R) to improve our potential launch of Ranexa in the first half of 2006," said Louis G. Lange, M.D., Ph.D., chairman and chief executive officer of CV Therapeutics.
About ACE Inhibitors
ACE inhibitors act to reduce hypertension by interfering with the conversion of angiotensin I to artery-constricting angiotensin II. Blocking the production of angiotensin II results in arterial vasodilation and an accompanying reduction in blood pressure.
ACE inhibitors currently are recommended as first-line therapy for treatment of hypertension in certain patient populations, because of their safety and efficacy. Most recently, the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation and Treatment of High Blood Pressure has recommended ACE inhibitors as one of the initial therapy choices for compelling comorbidities such as heart failure, postmyocardial infarction, high coronary disease risk, diabetes, chronic kidney disease and recurrent stroke prevention. ACEON(R) is only indicated for the treatment of patients with essential hypertension.
Certain ACE inhibitors, including ACEON(R), which have been shown to have an enhanced affinity for the tissues, are known as tissue-ACEs.
ACEON(R) is indicated for the treatment of patients with essential hypertension.
ACEON(R) offers continuous 24-hour blood pressure control with once-daily dosing. ACEON(R) may be used alone or with other classes of antihypertensives.
When used in pregnancy during the second and third trimesters, ACE inhibitors can cause injury and even death to the developing fetus. When pregnancy is detected, ACEON(R) should be discontinued as soon as possible.
ACEON(R) is contraindicated in patients known to be hypersensitive to this product or to any other ACE inhibitors and in patients with a history of angioedema related to previous treatment with an ACE inhibitor.
In the United States, perindopril is co-promoted under the brand name ACEON(R) by CV Therapeutics and Solvay Pharmaceuticals. In other parts of the world such as Europe, Canada and Australia, perindopril is marketed under several brand names, including Coversyl(R). Perindopril is one of the leading ACE inhibitors in Europe.
Source: Solvay Pharmaceuticals, Inc. and CV Therapeutics, Inc.